Skip to Content

Xembify Approval History

FDA Approved: Yes (First approved July 3, 2019)
Brand name: Xembify
Generic name: immune globulin subcutaneous, human - klhw
Dosage form: Injection
Company: Grifols
Treatment for: Primary Immunodeficiency Syndrome

Xembify (immune globulin subcutaneous, human- klhw) is a 20% immune globulin solution for subcutaneous injection indicated for treatment of Primary Humoral Immunodeficiency (PI).

Development History and FDA Approval Process for Xembify

DateArticle
Jul  4, 2019Approval FDA Approves Xembify (immune globulin subcutaneous) for Primary Immunodeficiencies

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide